Compare RGEN & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | KRYS |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 7.8B |
| IPO Year | 1995 | 2017 |
| Metric | RGEN | KRYS |
|---|---|---|
| Price | $112.94 | $263.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | $167.67 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 857.4K | 210.8K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 286.96 | 128.00 |
| EPS | 0.86 | ★ 6.84 |
| Revenue | $141,236,000.00 | ★ $389,130,000.00 |
| Revenue This Year | $14.30 | $38.74 |
| Revenue Next Year | $14.52 | $32.53 |
| P/E Ratio | $136.78 | ★ $39.42 |
| Revenue Growth | ★ 35.10 | 33.94 |
| 52 Week Low | $109.50 | $123.03 |
| 52 Week High | $175.77 | $298.30 |
| Indicator | RGEN | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 47.07 |
| Support Level | $111.29 | $254.53 |
| Resistance Level | $130.12 | $263.75 |
| Average True Range (ATR) | 6.03 | 8.98 |
| MACD | -1.13 | -0.36 |
| Stochastic Oscillator | 9.65 | 26.18 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.